EMA Authorised: Hopledo (carbidopa monohydrate;levodopa) — Zambon SpA

View source ↗

Summary

Hopledo, a fixed-dose combination of carbidopa monohydrate and levodopa, has been authorised by the EMA for Parkinson disease. The marketing authorization holde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Hopledo (carbidopa monohydrate;levodopa)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Zambon SpA. Decision date: 20/08/2026